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Abstract
Background: Community pharmacies provide a suitable setting to promote self-screening programs aimed at
enhancing the early detection of atrial fibrillation (AF). Developing and implementing novel community pharmacy
services (CPSs) is a complex and acknowledged challenge, which requires comprehensive planning and the
participation of relevant stakeholders. Co-design processes are participatory research approaches that can enhance
the development, evaluation and implementation of health services. The aim of this study was to co-design a
pharmacist-led CPS aimed at enhancing self-monitoring/screening of AF.
Methods: A 3-step co-design process was conducted using qualitative methods: (1) interviews and focus group
with potential service users (n = 8) to identify key needs and concerns; (2) focus group with a mixed group of
stakeholders (n = 8) to generate a preliminary model of the service; and (3) focus group with community pharmacy
owners and managers (n = 4) to explore the feasibility and appropriateness of the model. Data were analysed
qualitatively to identify themes and intersections between themes. The JeMa2 model to conceptualize pharmacy-
based health programs was used to build a theoretical model of the service.
Results: Stakeholders delineated: a clear target population (i.e., individuals ≥65 years old, with hypertension, with or
without previous AF or stroke); the components of the service (i.e., patient education; self-monitoring at home;
results evaluation, referral and follow-up); and a set of circumstances that may influence the implementation of the
service (e.g., quality of the service, competency of the pharmacist, inter-professional relationships, etc.). A number of
strategies were recommended to enable implementation (e.g.,. endorsement by leading cardiovascular
organizations, appropriate communication methods and channels between the pharmacy and the general medical
practice settings, etc.).
Conclusion: A novel and preliminary model of a CPS aimed at enhancing the management of AF was generated
from this participatory process. This model can be used to inform decision making processes aimed at adopting
and piloting of the service. It is expected the co-designed service has been adapted to suit existing needs of
patients and current care practices, which, in turn, may increase the feasibility and acceptance of the service when
it is implemented into a real setting.
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Background
Atrial fibrillation (AF) is one the most common heart
rhythm disorder. Globally, it is estimated that 30 million
individuals are diagnosed with AF [1]. Cardiovascular
morbidity and mortality related to AF remains high and
is primarily associated with cardiovascular death, heart
failure, stroke and hospitalisation [1]. Individuals with
AF have a three to five-fold risk of developing stroke [2]
with AF estimated to be a contributing factor of 25–30%
of all ischaemic strokes [3]. AF-related strokes are often
more catastrophic and disabling than strokes of other
origin [4]. However, in the majority of cases these
strokes are preventable, since in more than 25% of cases,
the stroke was the first indicator of a previously uniden-
tified AF. Prevention is two-fold, reliant on timely AF
diagnosis and optimisation of thromboprophylaxis [5].
Internationally, the proportion of undiagnosed AF is
estimated to be between 11% and 30% [3] ,which evi-
dence an obvious need for systematic community-based
screening programs. In 2016, the Atrial Fibrillation
Network, the European Heart Rhythm Association, and
others, have recommended the establishment of wide-
spread screening programs for AF in individuals aged
over 65, and those at high risk, including stroke
survivors [1]. To date, much attention has been directed
towards promoting opportunistic AF screening and
developing systematic screening programs. However, lim-
ited attention has been paid to the area of patient self-
monitoring and -screening of AF, which is a suitable, yet
underused practice [6]. Given the availability of blood
pressure (BP) monitoring devices that integrate reliable
algorithms to detect AF one could postulate that preven-
tion strategies may include the concept of patient self-
monitoring and screening [7–9]. Home BP monitoring is
a widely acknowledged practice adopted by many hyper-
tensive patients that enables multiple measurements of BP
over extended periods of time [10, 11]. Compared to an
opportunistic single-screen at one point in time, self-
monitoring for BP/AF at home potentially increases the
chance of detecting AF. Therefore, adopting automated
devices for BP monitoring that integrate reliable algo-
rithms to detect AF is a promising practice that may
enhance the diagnosis and management of AF and thus
reduce AF-related cardiovascular morbidity and mortality
in the long term [9].
Community pharmacies offer a broad and accessible
network of health facilities at the primary care level that
provide access to a large number of individuals at risk
who may be screened for a range of conditions [12].
Additionally, there is evidence that community phar-
macy services (CPSs) can positively influence patients’
behaviours, such as self-monitoring of BP [13, 14], and,
eventually, cardiovascular outcomes [15]. To date, previous
studies exploring AF-screening services in the community
pharmacy have used a single, in-pharmacy opportunistic
screening by a pharmacist as the principal detection
method [16, 17], yet no pharmacist-led CPSs that promote
self-monitoring of AF as the main screening method have
been found in the literature. Developing, implementing and
evaluating novel CPSs are complex challenges [18], which
require comprehensive planning and participation of rele-
vant stakeholders [19, 20].
Co-design processes are participatory research ap-
proaches that engage service users, healthcare profes-
sionals and any other key stakeholders with a vested
interest in a particular problem in developing (and
further implementing and evaluating) health services
[21, 22]. Having stakeholders working collaboratively
brings several benefits to the service planning process
that can eventually facilitate their adoption into practice
[23, 24]. Generally, it fosters co-learning, nurtures net-
working, develops stakeholders’ positive feelings of own-
ership on the planned service, and brings innovative
ideas, logistical and financial support. In their early
stages, co-design processes require stakeholders to
reflect on their own healthcare experiences, working to-
gether to identify relevant needs and priorities for
improvement and to devise strategies to address the
identified issues [22]. This facilitates not only an appro-
priate understanding of patients’ needs and existing gaps
in healthcare, but also of those circumstances that can
enable or hinder the delivery and implementation of the
service. As a result, co-designed health services are
adjusted to the specific context or environment in which
they are to be integrated, which, in turn, increases their
acceptability and feasibility [25]. Co-design processes
have been used in a broad range of healthcare settings
adopting diverse research approaches, generally qualita-
tive [26–29]. However, co-design has been infrequently
employed in the pharmacy setting, despite the potential
convenience as per existing service development and
implementation challenges. Hence, the aim of this study
was to use a stakeholder co-design approach to develop a
pharmacist-led CPS aimed at enhancing self-management
of AF (by promoting self-monitoring and screening).
Methods
A 3-step co-design process using qualitative methods
(i.e., focus groups and individual interviews) was
conducted to develop the aimed service. Overall, the
process sequentially engaged: (1) potential service
users to understand their needs and concerns and
inform the next steps, (2) a mixed group of service
stakeholders to work collaboratively and generate a
preliminary model of the service and (3) a group of
community pharmacy owners and managers to ini-
tially explore the feasibility and appropriateness of
the co-designed model.
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(1)Step 1: Exploring the views of potential service users.
A focus group and semi-structured interviews were
conducted with individuals over 65 years with
hypertension and/or AF. The focus group lasted
2.5 h and involved 4 individuals. Interviews were
conducted face-to-face (n = 2) or by phone (n = 2).
The focus group and interview guide is provided in
Additional file 1. All participants were fluent in
English. Individuals with a cognitive impairment, an
intellectual disability or a mental illness were excluded.
The aim of both the focus group and interviews was to
explore: (1) the knowledge/awareness, concerns and
needs of participants regarding AF, (2) their experiences
with AF, hypertension (including management and
monitoring) and health services; and (3) their opinions
about community pharmacists and a hypothetical CPS
aimed at self-screening/monitoring of AF. This latter part
included specific discussions about the device Microlife
BP A200 AFIB (Microlife Corp., Taipei, Taiwan), which
is a clinically validated BP measurement device that
integrates an algorithm for the evaluation of pulse
irregularity and the detection of AF during automated
BP measurement [7–9]. The educational material
developed by the company that has the rights to
distribute the device in Australia and funded this
research was assessed for appropriateness. Participants
were recruited through existing networks and a not-for-
profit association that organises social activities for the
elderly.
(2)Step 2: Delineating a preliminary model of the
service. A 4.5-h focus group with a mixed group of
stakeholders with a vested interest in the aimed CPS
was conducted. Stakeholders included 8 participants
who could directly or indirectly participate or have
an influence in the service, including: 1 potential
service user from the previous group; 2 community
pharmacy owners/managers/service providers; 1
general practitioner (GP); 1 cardiologist; 1 heart
failure nurse practitioner; 1 research nurse with
expertise in AF; and 1 representative from the
Australian Stroke Foundation. The aim of this focus
group was to delineate a preliminary model of the
CPS. The findings of the previous step were used to
inform the group discussions, which sequentially
addressed: (1) the target population of the service
(i.e., Which patients would most benefit from the
service?); (2) the service components, including
assessments by the pharmacists, interventions targeting
patients and healthcare providers, patient referral and
follow-up processes (i.e., How does a high-quality
pharmacy service for the targeted population look
like?); and (3) what are the circumstances that can
enable or hinder the delivery or implementation of the
service in the existing context (i.e., what should be
taken into account to integrate the service into
practice?). Between the second and third part of the
discussion, participants were given the educational
material for assessment. The focus group guide is
provided in Additional file 2. Stakeholders were
purposely selected and contacted by the research team
to bring a broad range of individuals and organizations
that allowed for a large expertise and experience and so
for designing a comprehensive service that suits current
needs of patients and the healthcare system.
(3)Step 3: Initial assessment of the feasibility and
appropriateness of the co-designed model. A 2-h
focus group with 4 community pharmacy owners
and managers was conducted. The aim of this focus
group was to further explore the feasibility and
appropriateness of the CPS and assess the professional
and economic implications of such a service from a
business perspective. Participants were provided with
an overview of the previously delineated model of the
service and asked for their views about such a model.
The same sequence, topics and questions delineated for
the previous focus group was used (Additional file 2).
Pharmacists were purposely selected and directly
contacted by the research team due to their previous
experience in CPS delivery.
All focus groups and interviews were facilitated by a
researcher (JT) with experience in qualitative research.
Focus groups took place within the university setting.
Individual interviews were held in a private meeting
room on campus, or were conducted by phone, accord-
ing to the wishes of participants. Interviews and focus
groups were audio-taped and transcribed verbatim.
Ethical approval for this study was obtained by the
Human Research Ethics Committee of the University of
Technology, Sydney (reference number: ETH16–0276).
All participants were appropriately informed about the
study and written consent was obtained.
Data analysis
Data were managed in QSR NVivo (10) and analysed
using Bazeley’s framework of ‘describe-compare-relate’
to identify themes and intersections between the themes
[30]. Data were analysed descriptively (i.e., categories
were formed directly from participant’s responses) by
one researcher (JT) and reported to the co-investigators
(DSH and CF) for their comment. Subsequent analyses
“challenged, extended and supported” the descriptive
nodes and focused on concepts emerging from observation
of all data at the more abstract level and on developing
themes from these concepts. This later stage of analysis in-
volved cycles of analysis whereby coding was reflected upon
critically as new themes were developed and revised if ne-
cessary. Developing themes were compared to each other
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and relevant associations and differences were recorded.
Themes were also compared between different focus
groups and in relation to occupation and background of
participants. Data from the two focus groups were analysed
together in an additional analytical process. Results of this
process were organised using the same structure as in the
focus group: (1) potential target population, (2) service
components, and (3) circumstances that may affect service
implementation. To assist in the identification of these
latter circumstances the list determinants of practice
described by Flottorp et al... (i.e., Tailored Implementation
in Chronic Disease checklist) was used [31].
Eventually, to organise the analysed data and build a
theoretical model of the service, the JeMa2 model to
conceptualize pharmacy-based health programs, as
described by Sabater-Hernández et al [20], vvpharmacist
interventions/pharmacy services can improve individ-
uals’ health and quality of life by immediately affecting
the determinants of both behavioural and environmental
causes of health. Moreover, the model hypothesizes the
relationships between pharmacy services and the context
in which such services are implemented. It envisages the
circumstances that can influence the implementation of
the service into routine practice and the set of strategies
and interventions aimed at supporting such implementa-
tion. The end result is the pharmacy-based health
program comprised of the pharmacy service and the
strategies and interventions that support its implementa-
tion, sustainability and overall impact [20].
Results
Exploring the views of potential service users
The range of age of the 8 individuals (7 women) who
participated in the focus group (n = 4) and the interviews
(n = 4) varied between 70 and 88 years old. Three partic-
ipants had a diagnosis of AF (an additional one was
unsure); including 2 with an implanted pacemakers, and
5 had hypertension (2 participants with both AF and
hypertension). One had neither condition, but had a
family history of hypertension. Four main categories
relevant to the research questions were identified from
the potential service user dataset:
 Awareness and knowledge of AF. Low awareness and
knowledge of AF was apparent among participants
who had AF and was non-existent among those who
did not. Indeed, one participant who had a pacemaker
was uncertain why she had it, but was sure that her
doctors had never used the term ‘atrial fibrillation’ in
discussions with her. The advertising materials that
were designed to increase awareness and knowledge
of AF were considered to be counter-productive for
that purpose, because of the negative cast of the
language used and the lack of explanation for the
medical terminology of ‘atrial fibrillation’ (Q1;
Additional file 3).
 Emotional distress. Emotional distress was found to
operate in two ways with regards to AF. Firstly,
participants with AF reported that AF symptoms are
very similar to the physical experience of emotional
distress and so it is difficult to distinguish between
‘being stressed’ and ‘going into AF’. Differentiating
the cause of certain physical symptoms of AF, such
as a ‘racing heart’, from the physical experience of
‘stressful life circumstances’ – which could also
result in an increased heart rate – was particularly
challenging (Q2; Additional file 3). This had
consequences for how they responded to and
managed these symptoms, as emotional stress could
be managed by relaxation techniques, yet AF may
sometimes require medication or medical
intervention, dependant on type of severity.
Secondly, emotional distress as a result of
frightening or unpleasant symptoms of AF could
be a motivating factor in learning more about the
condition and preparing for a future AF event.
The degree of emotional distress AF symptoms
caused participants appeared to influence their
awareness of the condition, particularly regarding
future AF attacks (Q3; Additional file 3) Those
who had experienced particularly frightening
symptoms when in AF were somewhat more
aware about their condition and prepared for its
consequences, such as having a plan for an AF
episode (Q4; Additional file 3).
 Perception of self-monitoring. One participant with
AF considered a benefit of having a monitoring
device was it helped to differentiate whether
emotional distress was due to AF or other causes
(Q5; Additional file 3). Most participants with AF
had experienced few symptoms (ever or recently)
and believed that their condition was currently
well-managed. Thus, AF did not have a significant
impact on their lives and monitoring the condition was
of low priority (Q6; Additional file 3). Those who had
hypertension felt similarly given the good control they
had achieved with medication only, although they
could see a need if they were worried or when their BP
was not well-controlled (Q7; Additional file 3). Two
participants who did not have AF or hypertension
expressed concerns about being over-serviced if they
engaged with self-monitoring (Q8; Additional file 3).
Participants were unconcerned by the possibility of AF
being detected at home, where a health
professional is not immediately present to
explain the findings. They were experienced with
diagnostic procedures and held sufficient trust in
their doctors and pharmacists to await their
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input before worrying or acting on the information
provided by the device (Q9; Additional file 3).
 Role of community pharmacists and pharmacy
services in in identifying and managing AF. There
was widespread support for pharmacists to assist
with the monitoring of AF. However, participants
were explicit and unanimous in their view that
pharmacist engagement in the management of AF
must be in partnership with GPs, who should also
recommend and support self-monitoring (Q10;
Additional file 3). It was also important that
participants’ privacy was maintained as a matter of
principle and that information sharing between
pharmacies and GPs must be conducted only with
their explicit permission (Q11; Additional file 3).
The fee for the service needed to be what participants
considered to be ‘reasonable’ and should vary
according to the individual level of government-
funded benefits (i.e., aged pension) and the payment
fees/conditions of services they currently access.
Participants who had no prior experience of monitoring
their BP or were particularly concerned about
hypertension were willing to pay a nominal fee of “up to
$25” AUD. However, some participants highlighted that
BP screening services were ‘already free’, so they
considered it unreasonable to charge an excessive fee to
explore for just one additional condition in addition to
BP (Q12; Additional file 3).
Building up the model of the service
Potential target population
There was a high level of agreement among stake-
holders as to whom the potential users of the phar-
macy service might be. It was quickly established that
those individuals who were 65 years or older, with
hypertension, with or without existing AF, and with
or without a previous history of stroke would be the
priority target group (Q13; Additional file 3). It was
noted that the service could be rolled out to Aborigi-
nal & Torres Strait Islander people as the second tier
of implementation.
Service components
Stakeholders defined three main components of the
service:
 Patient education. The low awareness and
knowledge of AF among high risk individuals
concerned many stakeholders, who considered
education to be a fundamental component of the
service. However, it was highlighted that close
attention to the language of education materials was
required so that it was understandable and
meaningful to the majority of patients, taking
account of varying levels of health literacy.
Responses from participants in all three focus
groups and interviews noted the need to avoid
‘medicalised’ language, encourage the use of plain
language, and explain key terms in the current
educational materials developed by the device
manufacturer (Q14; Additional file 3). Stakeholders
highlighted the need to use different methods,
techniques (e.g., pharmacists providing in-situ
demonstrations on how to use the device; patient
self-learning by taking information home) and
materials (e.g., booklets, information sheets,
websites, videos, podcast) in acknowledgement of
different learning styles (Q15; Additional file 3).
Furthermore, educational material for patients
should be endorsed by leading cardiovascular
organizations (including the heart and stroke
foundations and national cardiac societies and
colleges).
 Self-monitoring of AF/BP at home. Participants in
the mixed stakeholder focus group highlighted the
importance of implementing reliable programs that
follow acknowledged recommendations for self-
monitoring and employ accurate devices. They were
wary of the reliability of current self-monitoring
practices given the poor accuracy and performance
of many BP monitoring devices available to patients
on the market. Self-monitoring was suggested to be
conducted for 2–4 weeks (Q16; Additional file 3).
Patients must understand the device is not a
diagnostic tool and an electrocardiogram (ECG)
must be conducted when a positive AF screen is
detected (Q17; Additional file 3). Pharmacists in the
third focus group agreed on the inclusion of the
self-monitoring component and were adamant that
an isolated screening service in the pharmacy would
not be successful. They mentioned that few patients
felt a personal need/interest for AF screening and so
it was difficult to charge a fee. This makes isolated
AF/BP screening in the pharmacy an uneconomic
exercise (Q18; Additional file 3). Self-monitoring of
AF/BP was deemed different and more valuable than
solely in-pharmacy screening and that might
facilitate the remuneration of the service (Q19;
Additional file 3).
 Evaluating results, referral and follow-up. In-
pharmacy consultations were proposed by the mixed
group of stakeholders to ensure self-monitoring
occurred, and to process and interpret the results.
Pharmacy owners/managers acknowledged the value
of downloading, processing and discussing the
results with patients. They also saw the value of
preparing robust reports derived from reliable,
trustworthy technology and using technical language
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to communicate disease progress to GPs and other
healthcare providers. However, they were initially
doubtful of the potential for success of these follow-
up consultations since, normally, once a device is
sold, customers tend not return to the pharmacy
(Q20; Additional file 3). When AF or high BP is
detected a referral should occur with the possibility of
the pharmacist assisting by making the appointment
on behalf of the patient. The need to follow-up
patients after being referred to the GP was also
suggested, so as to check whether patients attend the
appointment or any decision was made as a result of
the service (Q21 and Q22; Additional file 3).
Circumstances that may enable or hinder the delivery or
implementation of the service (i.e., determinants of
pharmacy practice)
Apart from some key issues already identified above
(e.g., quality of the service, cost of the service to the pa-
tient, etc.), five main themes arose from the analysis of
the stakeholder data (see all the identified determinant
of pharmacy practice in Fig. 1):
 Service provider and qualification. It was agreed by
all stakeholders that the service must be provided by
a pharmacist with appropriate qualification and
should not be delegated to a lesser-qualified staff
member. This would lend the service the necessary
professionalism and legitimacy to allow consumers
to have confidence in the quality of service
(Q23; Additional file 3).
 Privacy in the pharmacy setting. All stakeholders
agreed on the need for a private consultation area to
provide the service, which also allows for a suitable
environment to perform an accurate BP reading
(Q24; Additional file 3). This need also aligned with
patients’ views on the importance of privacy and
confidentiality.
 Pharmacy staffing. Pharmacies needed to be staffed
by a sufficient number of pharmacists at any given
time so that the general business of the pharmacy
could continue whilst the service is provided
(Q25; Additional file 3). This may be difficult for
small, independently-owned pharmacies in which a
private consultation room may not exist. However,
there was concurrence across both stakeholder focus
groups that the aforementioned type of pharmacies
would be better placed to provide the service, as
they were considered to have a commitment to
health service provision over and above profit
(Q26; Additional file 3).
 Service remuneration. Stakeholders agreed the fee
for service should not be associated with the sale of
the device only, since not all services would progress
to sales and the profit margin is relatively low. It was
suggested that patients could pay a fee for both
Fig. 1 Theoretical model of the co-designed community pharmacy service
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renting the device and for the service of professional
advice. Renting the device was seen as low-cost
alternative to immediate purchase that allows
patients to testing the device and assessing its useful-
ness. Ultimately, this rental models might lead to a
greater number of sales (Q19; Additional file 3).
Pharmacists in the pharmacy focus group also
suggested that the manufacturer should provide
devices free of charge to pharmacies to establish the
service.
 Inter-professional relationships. Effective
communication between pharmacies and general
practices were emphasised as being especially
important by all stakeholders. Regular
communication with GPs was emphasised
particularly by doctors as a requirement to maximise
the success of the service. They recognised that
well-established communication channels were
important, but there were individual differences in
preferred modes of communication. Thus,
communication methods would need to be
formalised and agreed upon prior to the roll-out of
the service (Q27 and Q28; Additional file 3).
Pharmacists anticipated low levels of success in
communicating or collaborating with GPs due to
misunderstandings regarding professional boundaries
and the misinterpretation of the actions of
pharmacists (Q29; Additional file 3). They also
suggested that service users do not find it necessary
for pharmacists to share information with GPs and
many customers prefer to manage the information
exchange themselves (Q30; Additional file 3).
However, potential service users alluded to times
when it would be advantageous for their GPs and
pharmacists to discuss their situation without acting
as the ‘go-between’ (Q31; Additional file 3). The mixed
group of stakeholders suggested establishing regular
visits to the pharmacy by a nurse practitioner to deliver
the service or facilitate coordination/communication
between healthcare settings (Q32; Additional file 3).
However, pharmacists in the pharmacist focus group
did not support this suggestion.
Based on the JeMa2 model, all the information ob-
tained through the co-design process was organised to
create a pictorial representation of the CPS. As illus-
trated in Fig. 1, the depicted model delineates the phar-
macy service along with the causal chain that explains
how it is expected to work and generate its impact on
the defined target population. These are the relation-
ships between the specific components of the service;
the targeted determinants; the expected changes in
patients’ and physician practices; and the final health
outcomes of the service. Finally, the model recaps the
range of circumstances that were posed to influence the
implementation of the service, along with few strategies
that were advised to address some of those issues.
Discussion
This study summarises a 3-step co-design experience that
resulted in the development of a preliminary model of a
CPS aimed at encouraging self-monitoring/screening of
AF. This is considered a relevant first step to suitably inte-
grating community pharmacists with the management of
AF and hence taking advantage of the accessibility of such
a setting to reach a larger number of individuals in need.
Importantly, the co-design process integrated the con-
cerns, expectations and values of patients, along with the
cumulated experience, knowledge and skills of key health-
care professionals, who may implement, deliver or interact
with the service. As a result, it is expected the co-designed
service has been adapted to suit existing needs of patients
and current care practices, which, in turn, may increase
the feasibility and acceptance of the service when it is im-
plemented into a real setting.
The co-design process was predominantly driven by the
self-monitoring component, which provided the original
fundamentals for developing the new service and was estab-
lished as the central service component from the outset.
Overall, participant stakeholders agreed on the potential role
of pharmacists in encouraging self-monitoring/screening
practices and pursued to clearly understand how they would
be adequately integrated within the pharmacy setting to
enhance current AF care. Moreover, as in a previous study
[32], patients stated they would feel comfortable to self-
monitor their condition and then report the results to a
healthcare professional. A good example about how the self-
monitoring component drove the discussions in the co-de-
sign process can be found when defining the target popula-
tion. Participants stakeholders considered the target
population should have an anticipated interest, motivation or
need for self-monitoring and so to receive the service. Based
on that argument, stakeholders prioritised individuals with
existing hypertension as the target population. Also, due to
the increased risk of AF of hypertensive individuals [33], it
was argued the service’s AF detection rates and thus its effi-
ciency may be increased. Overall, the combination of both a
better approach for AF screening (based on repeated mea-
sures) and a more specific target population may enhance
the acceptance and feasibility of a service and overcome
certain implementation challenges compared to previous,
isolated AF screening programs in the community pharmacy
targeting broader populations [16, 17, 34, 35].
Patient education also emerged as a core component of
the co-designed service. This is consistent with existing
literature on educational needs in AF, which acknowledges
patient education lays the foundation to change patient’s
attitudes, behaviours and so achieve better outcomes and
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must address the two key challenges reported in this study
(i.e., enhance awareness/knowledge about AF and manage
the physiological component associated with AF) [36]. Be-
sides, given the self-monitoring component, patient edu-
cation also becomes relevant to ensure the quality of self-
monitoring [37], which is an acknowledged international
concern [10, 11, 38]. Education in this regard must ad-
dress the suitable recommendations for self-monitoring
[10, 11]. Importantly, additional educational efforts must
be directed to increasing awareness and uptake of AF
screening among patients for whom self-monitoring is
warranted, yet they are not fully cognisant of the benefits
of the practice to their individual circumstances.
In this co-design process, the JeMa2 model was used
to organise the gathered information and construct the
theoretical model of the CPS. The model allows for a
comprehensive depiction of the CPS beyond the compo-
nents of the service [20]. Firstly, the model encompasses
the set of behaviours (i.e., patients’ and physicians’ prac-
tices) and determinants of patients’ behaviours that are
immediately targeted by the CPS. These intermediate
variables show the ‘casual links’ that explain how the
CPS is expected to improve health and inform the
changes that must be assessed for the impact evaluation
of the CPS [39]. Secondly, the model addresses the con-
text in which the CPS will be implemented, including
the social, physical, economic, and policy environments.
Assessing and identifying the circumstances that can
positively or negatively influence implementation from
the outset of the health service planning process is cru-
cial for the early adaptation of services (i.e., adoption of
best methods, procedures or materials) to best fit exist-
ing healthcare practices and also for informing the de-
velopment of strategies and interventions to support the
implementation of the service into practice [25, 40].
It should be noted that despite the comprehensive ap-
proach adopted by the JeMa2 model, the model gener-
ated from this process is limited by the number of
stakeholders (19 in total) who participated in an, equally
restricted, number of co-design steps. Therefore, the re-
sulted model must be seen as a preliminary approach
that requires further development and decision-making
before being piloted in a real setting. For example, at the
service level, discussions, agreements or research are re-
quired to define a clear self-monitoring schedule for de-
tecting AF, or patient referral or follow-up criteria. To
date, guidance for recommendations to optimal method,
location and frequency of AF screening are not well
described within international AF guidelines. Therefore,
current recommendations for BP can be used as a start-
ing point [10, 41]. Also at the service level, a need for
conducting additional research to inform the adoption of
educational methods, techniques and materials that can
suit stakeholder’s needs, preferences, etc. is acknowledged.
At the contextual level, the list of circumstances that may
influence service implementation is not comprehensive
and further groundwork and research is needed to ensure
all key circumstances have been identified. Previous theory
and research on determinants of healthcare practice [31,
42] and, specifically, on barriers and facilitators to CPS
implementation [43, 44] may assist in this regard.
Similarly, additional work will be necessary to identify, se-
lect and precisely define the implementation strategies
and interventions once the most relevant determinants of
practice have been determined [45, 46].
Conclusions
This co-design process generated a preliminary, yet
novel model of a community pharmacy-based health
program that envisages the integration of community
pharmacists in the management of AF; particularly,
by promoting self-monitoring/screening of AF. As a result
of integrating the views of multiple stakeholders, the co-
designed service has been adapted to suit patients’ needs
and healthcare practices, which may increase its feasibility
and acceptance when implemented into practice. In
future, the model may inspire pharmacy service planners
and researchers to conduct further groundwork and re-
search aimed at developing the CPS and the implementa-
tion program. Furthermore, the model may serve to
prompt individual pharmacies (i.e., pharmacy owners or
managers) or leading organizations (e.g., professional, sci-
entific or governmental organizations) to make decisions
for adapting the CPS to their particular context and pilot
the service in a real-world setting.
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